Attached files

file filename
EX-21 - EX-21 - Biostar Pharmaceuticals, Inc.ex21.htm
EX-31.1 - EX-31.1 - Biostar Pharmaceuticals, Inc.ex31-1.htm
EX-32.2 - EX-32.2 - Biostar Pharmaceuticals, Inc.ex32-2.htm
10-K - 10-K - Biostar Pharmaceuticals, Inc.biostarpharma10k123115.htm
EX-31.2 - EX-31.2 - Biostar Pharmaceuticals, Inc.ex31-2.htm
EX-32.1 - EX-32.1 - Biostar Pharmaceuticals, Inc.ex32-1.htm
EX-23.2 - EX-23.2 - Biostar Pharmaceuticals, Inc.ex23-2.htm
EX-23.3 - EX-23.3 - Biostar Pharmaceuticals, Inc.ex23-3.htm
Exhibit 23.1
 
GRAPHIC
 
Consent of Independent Registered Public Accounting Firm



To the Board of Directors of
Biostar Pharmaceuticals, Inc.


We hereby consent to the incorporation by reference of our report dated April 14, 2016 with respect of the consolidated financial statements of Biostar Pharmaceuticals, Inc. as of and for the years ended December 31, 2015 and 2014 into the Annual Report on Form 10-K of Biostar Pharmaceuticals, Inc. for the year ended December 31, 2015, which report will be filed with the U.S. Securities and Exchange Commission on April 14, 2016.


 
 
/s/Mazars CPA Limited                                                                   
 
Mazars CPA Limited
Certified Public Accountants
 
Hong Kong
April 14, 2016